ClinicalTrials.gg
CompletedNCT03723395Updated Dec 18, 2019

A Drug-Drug Interaction Study in Healthy Volunteers of the Effects of Tucatinib

A Phase 1 interventional study of tucatinib and itraconazole in Drug-drug Interaction, sponsored by Seagen Inc.. Completed at 2 sites in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-12-18.

Sponsored by Seagen Inc. (part of Pfizer) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Dec 2018, 7 years 10 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
116
Allocation
Non-randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

This study is being done to look at how tucatinib could affect the way other drugs work. This study will look at healthy volunteers and how tucatinib affects their liver enzymes. Liver enzymes can change how drugs work in the body. There are 5 parts to this study. Parts A and C are looking at how the body breaks down tucatinib when there are lower levels of certain liver enzymes. Part B is looking at how the body breaks down tucatinib when there are high levels of certain liver and stomach enzymes. Parts D and E are looking at how tucatinib could change the levels of some liver and stomach enzymes in the body. This will help us know more about how tucatinib should be given to patients.

Read the detailed description

This is a fixed-sequence, drug-drug interaction study of tucatinib conducted in 5 parts in healthy subjects. Part A will evaluate the effect of the strong CYP3A4 inhibitor itraconazole on the pharmacokinetics (PK) of tucatinib. Part B will evaluate the effect of rifampin, a strong inducer of CYP3A4 and CYP2C8, on the PK of tucatinib. Part C will evaluate the effect of the strong CYP2C8 inhibitor gemfibrozil on the PK of tucatinib. Part D will evaluate the effects of tucatinib on the PK of substrate probes of the metabolizing enzymes CYP2C8 (repaglinide), CYP2C9 (tolbutamide), and CYP3A4 (midazolam). Part E will evaluate the effect of tucatinib on the PK of a substrate probe of the transporter P-gp (digoxin). Parts A, B, C, D, and E of the study are independent of one another and do not need to be conducted in a particular order.

02

Conditions studied

  • Drug-drug Interaction
03

In context

Lead sponsor

Seagen Inc. is the lead sponsor of 88 studies on the registry; 1 is open to participants now.

Of its 27 completed or terminated interventional studies of FDA-regulated products, 14 (52%) have results posted.

First submitted before Seagen Inc. became part of Pfizer.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • (BMI) between 18 and 32 kg/m\^2
  • In good health, determined be no findings from medical history, physical examination, and screening evaluations
  • Female subjects must be of nonchildbearing potential
  • Male subjects must agree to use or must be surgically sterile for at least 90 days prior to enrollment
  • Able to understand and sign form

Exclusion criteria

Exclusion Criteria:

  • Any condition affecting drug absorption (including stomach or intestinal surgery)
  • Significant history of metabolic, allergic, dermatological, hepatic, renal, hematological, pulmonary, cardiovascular, gastrointestinal, neurological, respiratory, endocrine, or psychiatric disorder
  • History of , intolerance, or allergy to any drug compounds, food, or other substance (unless approved by Investigator)
  • Participation in a clinical study involving an drug within the past 30 days
  • Use or intend to any prescription medications within 28 days prior to check in
  • Use of tobacco- or nicotine-containing products within 28 days prior to check in
  • History of hyperbilirubinemia
  • History of alcoholism or drug abuse within 2 years
  • History of regular alcohol consumption exceeding 7 drinks/week for female subjects or 14 drinks/week for male subjects
  • Positive hepatitis panel and/or positive (HIV) test
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
116 participants (actual)

Study arms

  • Experimental
    Part A

    Tucatinib plus Itraconazole

    Drug: tucatinib · Drug: itraconazole

  • Experimental
    Part B

    Tucatinib plus Rifampin

    Drug: tucatinib · Drug: rifampin

  • Experimental
    Part C

    Tucatinib plus Gemfibrozil

    Drug: tucatinib · Drug: gemfibrozil

  • Experimental
    Part D

    Tucatinib plus Repaglinide plus Tolbutamide plus Midazolam

    Drug: tucatinib · Drug: repaglinide · Drug: tolbutamide · Drug: midazolam

  • Experimental
    Part E

    Tucatinib plus Digoxin

    Drug: tucatinib · Drug: digoxin

Interventions

  • 300mg dose, orally administered

  • Drugitraconazole

    200mg dose

  • Drugrifampin

    600mg dose

  • Druggemfibrozil

    600mg tablets

  • 1mg dose

  • 500mg dose

  • Drugmidazolam

    2mg dose

  • Drugdigoxin

    0.5 mg dose

06

What researchers measure

Primary outcomes

  1. Area under the concentration-time curve (AUC) from time 0 to infinity

    PK parameters for tucatinib (Parts A, B, and C); repaglinide and its M4 metabolite (Part D), tolbutamide and its 4-hydroxytolbutamide metabolite (Part D), midazolam and its 1-hydroxymidazolam metabolite (Part D), and digoxin (Part E)

    Time frame: Up to 22 days

  2. AUC from time 0 to the time of the last quantifiable concentration

    PK parameters for tucatinib (Parts A, B, and C); repaglinide and its M4 metabolite (Part D), tolbutamide and its 4-hydroxytolbutamide metabolite (Part D), midazolam and its 1-hydroxymidazolam metabolite (Part D), and digoxin (Part E)

    Time frame: Up to 22 days

  3. Percentage extrapolation in AUC

    PK parameters for tucatinib (Parts A, B, and C); repaglinide and its M4 metabolite (Part D), tolbutamide and its 4-hydroxytolbutamide metabolite (Part D), midazolam and its 1-hydroxymidazolam metabolite (Part D), and digoxin (Part E)

    Time frame: Up to 22 days

  4. Maximum observed concentration

    PK parameters for tucatinib (Parts A, B, and C); repaglinide and its M4 metabolite (Part D), tolbutamide and its 4-hydroxytolbutamide metabolite (Part D), midazolam and its 1-hydroxymidazolam metabolite (Part D), and digoxin (Part E)

    Time frame: Up to 22 days

  5. Time of maximum observed concentration

    PK parameters for tucatinib (Parts A, B, and C); repaglinide and its M4 metabolite (Part D), tolbutamide and its 4-hydroxytolbutamide metabolite (Part D), midazolam and its 1-hydroxymidazolam metabolite (Part D), and digoxin (Part E)

    Time frame: Up to 22 days

  6. Apparent terminal elimination half-life

    PK parameters for tucatinib (Parts A, B, and C); repaglinide and its M4 metabolite (Part D), tolbutamide and its 4-hydroxytolbutamide metabolite (Part D), midazolam and its 1-hydroxymidazolam metabolite (Part D), and digoxin (Part E)

    Time frame: Up to 22 days

  7. Apparent total clearance

    PK parameters for tucatinib (Parts A, B, and C); repaglinide (Part D), tolbutamide (Part D), midazolam (Part D), and digoxin (Part E).

    Time frame: Up to 22 days

  8. Apparent volume of distribution

    PK parameters for tucatinib (Parts A, B, and C); repaglinide (Part D), tolbutamide (Part D), midazolam (Part D), and digoxin (Part E).

    Time frame: Up to 22 days

  9. Metabolite-to-parent ratio based on AUC

    PK parameters for M4 metabolite, 4-hydroxytolbutamide metabolite, and 1-hydroxymidazolam metabolite (Part D only)

    Time frame: Up to 22 days

Secondary outcomes

  1. Incidence of adverse events (AEs)

    Parts A, B, C, D, and E (all)

    Time frame: Up to 58 days

  2. Incidence of laboratory abnormalities

    Parts A, B, C, D, and E (all)

    Time frame: Up to 58 days

  3. 12-lead electrocardiogram (ECG) assessment

    PR, RR, QRS, and QT interval. Parts A, B, C, D, and E (all)

    Time frame: Up to 58 days

  4. Vital signs measurements

    Oral temperature. Parts A, B, C, D, and E (all)

    Time frame: Up to 58 days

  5. Vital signs measurements

    Respiratory rate. Parts A, B, C, D, and E (all)

    Time frame: Up to 58 days

  6. Vital signs measurements

    Blood pressure (systolic and diastolic). Parts A, B, C, D, and E (all)

    Time frame: Up to 58 days

  7. Vital signs measurements

    Heart rate. Parts A, B, C, D, and E (all)

    Time frame: Up to 58 days

  8. Physical examinations

    Incidence of AEs resulting from clinically significant findings in examination of general appearance, skin, thorax/lungs, cardiovascular system, and abdomen. Parts A, B, C, D, and E (all)

    Time frame: Up to 58 days

  9. AUC within a dosing interval

    PK parameters of tucatinib and ONT-993; Parts D and E only

    Time frame: Up to 15 days

  10. AUC from time 0 to infinity

    PK parameters of tucatinib and ONT-993; Parts D and E only

    Time frame: Up to 8 days

  11. AUC from time 0 to the time of the last quantifiable concentration

    PK parameters of tucatinib and ONT-993; Parts D and E only

    Time frame: Up to 15 days

  12. Percentage extrapolation in AUC

    PK parameters of tucatinib and ONT-993; Parts D and E only

    Time frame: Up to 15 days

  13. Maximum observed concentration

    PK parameters of tucatinib and ONT-993; Parts D and E only

    Time frame: Up to 15 days

  14. Time of maximum observed concentration

    PK parameters of tucatinib and ONT-993; Parts D and E only

    Time frame: Up to 15 days

  15. Apparent terminal elimination half-life

    PK parameters of tucatinib and ONT-993; Parts D and E only

    Time frame: Up to 15 days

  16. Apparent total clearance

    PK parameter of tucatinib; Parts D and E only

    Time frame: Up to 8 days

  17. Apparent total clearance at steady state

    PK parameter of tucatinib; Parts D and E only

    Time frame: Up to 15 days

  18. Apparent volume of distribution

    PK parameter of tucatinib; Parts D and E only

    Time frame: Up to 8 days

  19. Apparent volume of distribution at steady state

    PK parameter of tucatinib; Parts D and E only

    Time frame: Up to 15 days

  20. Accumulation ratio

    PK parameters of tucatinib and ONT-993; Parts D and E only

    Time frame: Up to 15 days

  21. Metabolite-to-parent ratio based on AUC

    PK parameter of ONT-993; Parts D and E only

    Time frame: Up to 15 days

07

Study locations

2 sites
  • Covance Clinical Research Unit
    Daytona Beach, Florida 32117, United States
  • Covance Clinical Research Unit
    Dallas, Texas 75247, United States
08

References and documents

Publications

  • Topletz-Erickson A, Lee A, Rustia EL, Sun H, Mayor JG, Abdulrasool LI, Walker L, Endres CJ. Evaluation of Safety and Clinically Relevant Drug-Drug Interactions with Tucatinib in Healthy Volunteers. Clin Pharmacokinet. 2022 Oct;61(10):1417-1426. doi: 10.1007/s40262-022-01144-z. Epub 2022 Aug 6. PubMed 35931943 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2018 to primary completion in Dec 2018, 3 months.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 24, 2018
First posted
Oct 29, 2018
StartActual
Sep 17, 2018
Primary completionActual
Dec 21, 2018
CompletionActual
Dec 28, 2018
Last update
Dec 18, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 18, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03723395
Lead sponsor
Seagen Inc.
Responsible party
Sponsor
First posted
Oct 29, 2018
Start date
Sep 17, 2018
Primary completion
Dec 21, 2018
Completion
Dec 28, 2018
Last update
Dec 18, 2019

Study contacts

Alex Vo, PhD
study director · Seagen Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tucatinib

Start the discussion